Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients

被引:31
|
作者
Andrews, Louise M. [1 ]
Riva, Natalia [1 ,2 ]
de Winter, Brenda C. [1 ]
Hesselink, Dennis A. [3 ]
de Wildt, Saskia N. [4 ,5 ]
Cransberg, Karlien [6 ]
van Gelder, Teun [1 ,3 ]
机构
[1] Erasmus MC, Univ Med Ctr Rotterdam, Dept Hosp Pharm, NL-3000 CA Rotterdam, Netherlands
[2] Hosp Pediat JP Garrahan, Unidad Farmacocinet Clin, Buenos Aires, DF, Argentina
[3] Erasmus MC, Univ Med Ctr Rotterdam, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[4] Erasmus MC, Sophia Childrens Hosp, Intens Care, NL-3000 CA Rotterdam, Netherlands
[5] Erasmus MC, Sophia Childrens Hosp, Dept Pediat Surg, NL-3000 CA Rotterdam, Netherlands
[6] Erasmus MC, Sophia Childrens Hosp, Div Nephrol, Dept Pediat, NL-3000 CA Rotterdam, Netherlands
关键词
algorithm; ciclosporin; dose; equation; immunosuppressive drugs; kidney; liver; mycophenolic acid; pharmacokinetics; tacrolimus; therapeutic drug monitoring; transplantation; POPULATION PHARMACOKINETIC ANALYSIS; MYCOPHENOLIC-ACID PHARMACOKINETICS; HIV-INFECTED PATIENTS; RENAL-TRANSPLANT; KIDNEY-TRANSPLANTATION; ACUTE REJECTION; CYCLOSPORINE PHARMACOKINETICS; TACROLIMUS CONCENTRATIONS; CALCINEURIN-INHIBITORS; CLINICAL PHARMACOKINETICS;
D O I
10.1517/17425255.2015.1033397
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Starting doses of tacrolimus and ciclosporin are typically chosen on a calculated mg/kg bodyweight basis. After initiation of treatment, doses are adjusted with therapeutic drug monitoring (TDM). This trial-and-error approach has been accepted by most physicians and pharmacists involved in the care of transplanted patients. Areas covered: Dosing algorithms have only fairly recently been proposed to better individualize the starting dose. This review provides an overview of all the currently available dosing algorithms in adult and children for the starting dose of ciclosporin, tacrolimus and mycophenolic acid. In these algorithms, multiple other covariates influencing the starting dose, such as age, hematocrit, comedication and genotype are taken into account. After selecting the starting dose with an algorithm and after initiation of treatment, TDM will, however, remain necessary. Whether or not implementation of such algorithms will improve clinical outcome remains to be demonstrated. Expert opinion: First of all an algorithm needs to be validated, against an independent dataset. Second, in a prospective study the algorithm should prove to reduce the time to reach the target concentration, and to reduce the number of patients with drug concentrations (far) outside the therapeutic window. Finally, a clinical trial demonstrating a benefit on clinical outcome will be crucial in achieving broad acceptance of calculating starting dose using individualized dosing algorithms.
引用
收藏
页码:921 / 936
页数:16
相关论文
共 50 条
  • [41] The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients
    Giovanni Montini
    Francesca Ujka
    Cristina Varagnolo
    Luciana Ghio
    Fabrizio Ginevri
    Luisa Murer
    Basile S. Thafam
    Carla Carasi
    Graziella Zacchello
    Mario Plebani
    Pediatric Nephrology, 2006, 21 : 719 - 724
  • [42] Pharmacogenetics and immunosuppressive drugs in solid organ transplantation
    van Gelder, Teun
    van Schaik, Ron H.
    Hesselink, Dennis A.
    NATURE REVIEWS NEPHROLOGY, 2014, 10 (12) : 725 - 731
  • [43] Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients
    Vezina, Heather E.
    Brundage, Richard C.
    Balfour, Henry H., Jr.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (02) : 343 - 352
  • [44] Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study
    Safdar, Nasia
    Smith, Jeannina
    Knasinski, Valerie
    Sherkow, Colleen
    Herrforth, Casey
    Knechtle, Stuart
    Andes, David
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2010, 66 (01) : 7 - 15
  • [45] Variables Associated With Hyperkalemic Renal Tubular Acidosis in Solid Organ Transplant Recipients
    Mohib, Othmane
    Vanderhulst, Julien
    Catalano, Concetta
    Roussoulieres, Ana
    Knoop, Christiane
    Lemoine, Alain
    Baudoux, Thomas
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [46] Pharmacokinetics of Tacrolimus in Pregnant Solid-Organ Transplant Recipients: A Retrospective Study
    Versluis, Jorn
    Bourgonje, Arno R.
    Touw, Daan J.
    Meinderts, Jildau R.
    Prins, Jelmer R.
    de Jong, Margriet F. C.
    Mian, Paola
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (04) : 428 - 436
  • [47] Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs
    Kurzawski, Mateusz
    Drozdzik, Marek
    PHARMACOGENOMICS, 2013, 14 (09) : 1099 - 1118
  • [48] Antibody immunosuppressive therapy in solid-organ transplant Part I
    Mahmud, Nadim
    Klipa, Dusko
    Ahsan, Nasimul
    MABS, 2010, 2 (02) : 148 - 156
  • [49] Important considerations for drugs, nutritional, and herbal supplements in pediatric solid organ transplant recipients
    Pilch, Nicole A.
    Sell, Megan L.
    McGhee, William
    Venkataramanan, Raman
    PEDIATRIC TRANSPLANTATION, 2021, 25 (01)
  • [50] Donor-Derived Infections in Solid Organ Transplant Recipients
    Grossi, P. A.
    Fishman, J. A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : S19 - S26